ArticleProceedings of the National Academy of Sciences of the United States of America2025
Next-generation rifamycins for the treatment of mycobacterial infections.
Abstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction.Journal of medicinal chemistry · 2026Article
- Induced alanine auxotrophy as a therapeutic strategy against Mycobacterium tuberculosis.Research square · 2026Article
- Mycobacterial cell division arrest and smooth-to-rough envelope transition using CRISPRi-mediated genetic repression systems.FEBS open bio · 2026Article
- Induced alanine auxotrophy as a therapeutic strategy againstbioRxiv : the preprint server for biology · 2026Article
- Review
- NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species.Scientific reports · 2026Article
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus.The Journal of antimicrobial chemotherapy · 2026Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2026 Update for Clinicians and Scientists.Pathogens & immunity · 2026Review
- Prodrug florfenicol amine is activated by intrinsic resistance to target Mycobacterium abscessus.Nature microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.ORCID 0000-0001-9470-5009
Tian LanDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
Uday S GanapathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Chui Fann WongCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Jickky P SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Diana C JimenezMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.
Ilham M AlshiraihiMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.
Ha LamMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.
Suyapa RodriguezCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Min XieCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Maritza Soto-OjedaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.ORCID 0000-0002-9212-0258
William WheatMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.ORCID 0000-0003-4229-3617
Nathan C DillmanDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
Kateryna KostenkovaDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
Jake SchmittDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
Lea MannInstitut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Adrian RichterInstitut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Peter ImmingInstitut für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany.
Jansy SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Firat KayaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.ORCID 0000-0001-8655-2065
Sindhuja ParuchuriCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Betelhem TatekCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.ORCID 0000-0001-9469-7192
Camilla FolvarCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Julianna ProiettoCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Matthew ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.
Mercedes Gonzalez-JuarreroMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523.
Courtney C AldrichDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455.
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110.ORCID 0000-0002-9604-9452
Funding
Therapeutics for drug-resistant bacteria: aryl myxopyronins and arylalkylcarboxamido phloroglucinolsU19AI142731 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI PERLIN, DAVID S · 2019 to 2023
$33.9MTherapeutics for drug-resistant bacteria: arylmyxopyroninsU19AI189168 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI RICHARD H. EBRIGHT · 2025 to 2026
$22.7MDiscovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0MOptimization of rifamycins to overcome intrinsic resistance of nontuberculous mycobacteria to improve treatment of NTM lung diseaseR01AI177342 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Courtney C Aldrich, Thomas Dick · 2023 to 2026
$3.4MShorter and more effective oral regimens for M. abscessus pulmonary diseaseR01AI184502 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Thomas Dick · 2025 to 2026
$1.8MDeutsche Forschungsgemeinschaft (DFG) 432291016HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI142731 R01AI132374NIAID NIH HHS R01 AI132374NIAID NIH HHS R01 AI177342NIAID NIH HHS R01 AI184502NIAID NIH HHS U19 AI142731NIAID NIH HHS U19 AI189168
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anti-Bacterial AgentsMycobacterium abscessusMycobacterium Infections, NontuberculousRifamycinsAnimalsCytochrome P-450 CYP3AHumansMiceMicrobial Sensitivity TestsMycobacterium tuberculosisRifabutinAnti-Bacterial AgentsCYP3A4 protein, humanCytochrome P-450 CYP3ARifabutinRifamycinsdrug discoveryMycobacterium abscessuspreclinical development candidatepulmonary infectionrifamycin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.